Search
Search Results
##search.searchResults.foundPlural##
-
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2123PDF: 1692HTML: 377 -
HODGKIN LYMPHOMA IN OLDER PATIENTS: AN ORPHAN DISEASE?
2882PDF: 1360HTML: 3569Untitled: 192Untitled: 202Untitled: 177 -
PROLIFERATION AND APOPTOSIS OF B-CELL LYMPHOMA CELLS UNDER TARGETED REGULATION OF FOXO3 BY miR-155 miR-155, FOXO3, B-cell lymphoma, proliferation, apoptosis, clinical characteristics
766PDF: 89HTML: 138 -
THE ROLE OF SLC22A4 IN ACUTE MYELOID LEUKEMIA
477PDF: 243HTML: 78 -
TRANSCRIPTOME ANALYSIS OF BETA-CATENIN-RELATED GENES IN CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS FROM PATIENTS WITH AML Transcriptome analysis of beta-catenin-related genes in AML
1042PDF: 1154Suppl. Files: 569HTML: 88 -
RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM
1190PDF: 1062HTML: 201 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1375HTML: 394PDF: 819 -
RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES
3771PDF: 1661HTML: 11590Figures Haase: 198 -
INTEREST IN DETERMINING THE CD34+ CD38- PHENOTYPE IN THE DIAGNOSIS AND PROGNOSIS OF ACUTE LEUKEMIA IN ABIDJAN – CÔTE D’IVOIRE
1957PDF: 711HTML: 683Table1: patient's characteristics: 155Table 2: profile of each patient: 178 -
PROGNOSTIC FACTORS IN HODGKIN LYMPHOMA
3310PDF: 1963HTML: 7472 -
PLASMACELL NEOPLASMS WITH SPREADING IN THE BLOOD AND TISSUES: EXTRAMEDULLARY MYELOMA DISEASE A RARE AGGRESSIVE FORM OF MULTIPLE MYELOMA (First of two parts) Extra Medullary Myeloma
2449HTML: 271PDF: 868 -
DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA
9051PDF: 6057HTML: 87956Fig.1b: 184Fig.1c: 188Fig.2a: 176Fig.2b: 175Fig.4: 188Fig.2c: 183Fig.3: 181Tab.1: 225Tab.2: 206Tab.3: 188Tab.4: 220Fig1a: 181 -
EPIDEMIOLOGICAL OVERVIEW OF HODGKIN LYMPHOMA ACROSS THE MEDITERRANEAN BASIN
3531PDF: 1177HTML: 4998Incidence age-standardized rates for HL across the Mediterranean basin: 201 -
NON-SECRETORY MYELOMA: READY FOR A NEW DEFINITION?
3249PDF: 1709HTML: 1084 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2580PDF: 798HTML: 5214 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3584PDF: 886HTML: 6711 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1525PDF: 941HTML: 222 -
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3549PDF: 2411HTML: 1463 -
HEPARIN-BINDING PROTEIN AS A DIAGNOSTIC AND PROGNOSTIC MARKER OF INFECTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS Heparin-binding protein in adult patients
2196PDF: 989HTML: 147Suppl. Files: 512 -
SOLITARY PLASMACYTOMA
3851PDF: 2175HTML: 1221fIGURES 1,2: 213 -
TYROSINE KINASE INHIBITORS AND PREGNANCY
3557PDF: 1635HTML: 2674 -
Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio
2169PDF: 1586HTML: 265 -
IMMUNOGLOBULIN GENE REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHT INTO ANTIGEN SELECTION AND MICROENVIRONMENTAL INTERACTIONS
3055PDF: 875HTML: 7163Kost Fig1: 182Kost Fig 2: 177Kost Fig3: 174Kost Fig 4: 190Kost Fig5: 184Kost fig 6: 173 -
-
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
2452PDF: 784HTML: 1735 -
MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
3935PDF: 1492HTML: 9188Untitled: 277Untitled: 183Untitled: 168Untitled: 164Untitled: 180Untitled: 338 -
-
MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
2760PDF: 1118HTML: 3283 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
3994PDF: 1051HTML: 3590Untitled: 177Cneo. Fig.1: 113Untitled: 104Untitled: 126Untitled: 131 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2801PDF: 1007HTML: 5519







